Literature DB >> 26666920

Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program.

Patricia A Bradford1, Krystyna M Kazmierczak2, Douglas J Biedenbach3, Mark G Wise3, Meredith Hackel3, Daniel F Sahm3.   

Abstract

The increasing use of carbapenems for treating multidrug-resistant (MDR) Gram-negative bacterial infections has contributed to the global dissemination of carbapenem-resistant Enterobacteriaceae (CRE). Serine and metallo-β-lactamases (MBLs) that hydrolyze carbapenems have become prevalent and endemic in some countries, necessitating the use of older classes of agents, such as colistin. A total of 19,719 isolates of Enterobacteriaceae (excluding Proteeae and Serratia spp., which have innate resistance to colistin) were collected from infected patients during 2012 and 2013 in a global surveillance program and tested for antimicrobial susceptibility using CLSI methods. Isolates of CRE were characterized for carbapenemases and extended-spectrum β-lactamases (ESBLs) by PCR and sequencing. Using EUCAST breakpoints, the rate of colistin susceptibility was 98.4% overall, but it was reduced to 88.0% among 482 carbapenemase-positive isolates. Colistin susceptibility was higher among MBL-positive isolates (92.6%) than those positive for a KPC (87.9%) or OXA-48 (84.2%). Of the agents tested, only tigecycline (MIC90, 2 to 4 μg/ml) and aztreonam-avibactam (MIC90, 0.5 to 1 μg/ml) consistently tested with low MIC values against colistin-resistant, ESBL-positive, and carbapenemase-positive isolates. Among the 309 (1.6%) colistin-resistant isolates from 10 species collected in 38 countries, 58 carried a carbapenemase that included KPCs (38 isolates), MBLs (6 isolates), and OXA-48 (12 isolates). These isolates were distributed globally (16 countries), and 95% were Klebsiella pneumoniae. Thirty-nine (67.2%) isolates carried additional ESBL variants of CTX-M, SHV, and VEB. This sample of Enterobacteriaceae demonstrated a low prevalence of colistin resistance overall. However, the wide geographic dispersion of colistin resistance within diverse genus and species groups and the higher incidence observed among carbapenemase-producing MDR pathogens are concerning.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26666920      PMCID: PMC4775915          DOI: 10.1128/AAC.01870-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatment.

Authors:  Shudan Chen; Fupin Hu; Xuelian Zhang; Xiaogang Xu; Yang Liu; Demei Zhu; Honghai Wang
Journal:  J Clin Microbiol       Date:  2011-09-07       Impact factor: 5.948

Review 2.  Susceptibility testing of the polymyxins: where are we now?

Authors:  Romney M Humphries
Journal:  Pharmacotherapy       Date:  2014-10-20       Impact factor: 4.705

3.  In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing Klebsiella pneumoniae is associated with low-dosage colistin treatment.

Authors:  Antonio Cannatelli; Vincenzo Di Pilato; Tommaso Giani; Fabio Arena; Simone Ambretti; Paolo Gaibani; Marco Maria D'Andrea; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

4.  Colistin heteroresistance in Enterobacter cloacae is associated with cross-resistance to the host antimicrobial lysozyme.

Authors:  Brooke A Napier; Victor Band; Eileen M Burd; David S Weiss
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

Review 5.  Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.

Authors:  Matthew E Falagas; Drosos E Karageorgopoulos; Patrice Nordmann
Journal:  Future Microbiol       Date:  2011-06       Impact factor: 3.165

6.  Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study.

Authors:  Olympia Zarkotou; Spyros Pournaras; Evangelia Voulgari; Georgios Chrysos; Athanassios Prekates; Dionysios Voutsinas; Katerina Themeli-Digalaki; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2010-04-07       Impact factor: 5.948

7.  Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin.

Authors:  K Kontopoulou; E Protonotariou; K Vasilakos; M Kriti; A Koteli; E Antoniadou; D Sofianou
Journal:  J Hosp Infect       Date:  2010-06-17       Impact factor: 3.926

8.  Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013.

Authors:  Sibylle H Lob; Krystyna M Kazmierczak; Robert E Badal; Meredith A Hackel; Samuel K Bouchillon; Douglas J Biedenbach; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

9.  First report of IMI-1-producing colistin-resistant Enterobacter clinical isolate in Ireland, March 2013.

Authors:  T W Boo; N O'Connell; L Power; M O'Connor; J King; E McGrath; R Hill; K L Hopkins; N Woodford
Journal:  Euro Surveill       Date:  2013-08-01

10.  Outbreak of a cluster with epidemic behavior due to Serratia marcescens after colistin administration in a hospital setting.

Authors:  Andrea Karina Merkier; María Cecilia Rodríguez; Ana Togneri; Silvina Brengi; Carolina Osuna; Mariana Pichel; Marcelo H Cassini; Daniela Centrón
Journal:  J Clin Microbiol       Date:  2013-05-22       Impact factor: 5.948

View more
  30 in total

1.  In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Boudewijn L M de Jonge; Meredith A Hackel; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.

Authors:  Zackery P Bulman; Michael J Satlin; Liang Chen; Barry N Kreiswirth; Beom Soo Shin; Thomas J Walsh; Patricia N Holden; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Verification of an Automated, Digital Dispensing Platform for At-Will Broth Microdilution-Based Antimicrobial Susceptibility Testing.

Authors:  Kenneth P Smith; James E Kirby
Journal:  J Clin Microbiol       Date:  2016-06-22       Impact factor: 5.948

4.  Detection of Colistin Resistance Gene mcr-1 in Hypervirulent Klebsiella pneumoniae and Escherichia coli Isolates from an Infant with Diarrhea in China.

Authors:  Dan-Xia Gu; Yong-Lu Huang; Ji-Hua Ma; Hong-Wei Zhou; Ying Fang; Jia-Chang Cai; Yan-Yan Hu; Rong Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 5.  Polymyxin Resistance in Gram-negative Pathogens.

Authors:  Pavithra Srinivas; Kaitlyn Rivard
Journal:  Curr Infect Dis Rep       Date:  2017-09-11       Impact factor: 3.725

Review 6.  The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.

Authors:  Ann Marie Porreca; Kaede V Sullivan; Jason C Gallagher
Journal:  Curr Infect Dis Rep       Date:  2018-05-05       Impact factor: 3.725

7.  A Novel Deletion Mutation in pmrB Contributes to Concurrent Colistin Resistance in Carbapenem-Resistant Escherichia coli Sequence Type 405 of Clinical Origin.

Authors:  Ching-Hsun Wang; L Kristopher Siu; Feng-Yee Chang; Yu-Kuo Tsai; Yi-Tsung Lin; Sheng-Kang Chiu; Li-Yueh Huang; Jung-Chung Lin
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

8.  LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48.

Authors:  Juan A Vallejo; Marta Martínez-Guitián; Juan C Vázquez-Ucha; Concepción González-Bello; Margarita Poza; John D Buynak; Christopher R Bethel; Robert A Bonomo; German Bou; Alejandro Beceiro
Journal:  J Antimicrob Chemother       Date:  2016-04-28       Impact factor: 5.790

9.  Genomic and Molecular Characterization of Clinical Isolates of Enterobacteriaceae Harboring mcr-1 in Colombia, 2002 to 2016.

Authors:  Sandra Yamile Saavedra; Lorena Diaz; Magdalena Wiesner; Adriana Correa; Stefany Alejandra Arévalo; Jinnethe Reyes; Andrea Melissa Hidalgo; Elsa de la Cadena; Marcela Perenguez; Lucy Angeline Montaño; Javier Ardila; Rafael Ríos; María Victoria Ovalle; Paula Díaz; Paola Porras; Maria V Villegas; Cesar A Arias; Mauricio Beltrán; Carolina Duarte
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

10.  In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.

Authors:  Krystyna M Kazmierczak; Patricia A Bradford; Gregory G Stone; Boudewijn L M de Jonge; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.